Evidence for the involvement of matrix metalloproteinases in the cardiovascular effects produced by nicotine

European Journal of Pharmacology

Volumn 627, Issue 1-3, 2010, Pages 216-222

  Jacob Ferreira, Anna L B ^a   Palei, Ana C T ^a   Cau, Stefany B ^b   Moreno Jr , Heitor ^a   Martinez, Marcio L L ^b   Izidoro Toledo, Tatiane C ^b   Gerlach, Raquel F ^b   Tanus Santos, Jose E ^b  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Endothelial dysfunction; Matrix metalloproteinase; Nicotine

Indexed keywords

ACETYLCHOLINE; DOXYCYCLINE; GELATINASE A; GELATINASE B; NICOTINE; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTERY DILATATION; ARTICLE; CARDIOVASCULAR EFFECT; CONTROLLED STUDY; DRUG MECHANISM; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME RELEASE; HYPERTENSION; MALE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RAT; SMOKING; SMOOTH MUSCLE FIBER;

ANIMALS; AORTA; CARDIOVASCULAR SYSTEM; CELL LINE; DOXYCYCLINE; ENDOTHELIAL CELLS; ENZYME INHIBITORS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MYOCYTES, SMOOTH MUSCLE; NICOTINE; RATS; TIME FACTORS;

EID: 73449101781     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.10.057     Document Type: Article

References (49)

1. Ambrose J.A., and Barua R.S. The pathophysiology of cigarette smoking and cardiovascular disease: an update. J. Am. Coll. Cardiol. 43 (2004) 1731-1737
2. Benowitz N.L., and Jacob III P. Daily intake of nicotine during cigarette smoking. Clin. Pharmacol. Ther. 35 (1984) 499-504
3. Bond M., Chase A.J., Baker A.H., and Newby A.C. Inhibition of transcription factor NF-kappaB reduces matrix metalloproteinase-1, -3 and -9 production by vascular smooth muscle cells. Cardiovasc. Res. 50 (2001) 556-565
4. Carty C.S., Soloway P.D., Kayastha S., Bauer J., Marsan B., Ricotta J.J., and Dryjski M. Nicotine and cotinine stimulate secretion of basic fibroblast growth factor and affect expression of matrix metalloproteinases in cultured human smooth muscle cells. J. Vasc. Surg. 24 (1996) 927-934 discussion 934-925
5. Castro M.M., Rizzi E., Figueiredo-Lopes L., Fernandes K., Bendhack L.M., Pitol D.L., Gerlach R.F., and Tanus-Santos J.E. Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats. Atherosclerosis 198 (2008) 320-331
6. Castro M.M., Rizzi E., Rascado R.R., Nagassaki S., Bendhack L.M., and Tanus-Santos J.E. Atorvastatin enhances sildenafil-induced vasodilation through nitric oxide-mediated mechanisms. Eur. J. Pharmacol. 498 (2004) 189-194
7. Castro M.M., Rizzi E., Rodrigues G.J., Ceron C.S., Bendhack L.M., Gerlach R.F., and Tanus-Santos J.E. Antioxidant treatment reduces matrix metalloproteinase-2-induced vascular changes in renovascular hypertension. Free Radic. Biol. Med. 46 (2009) 1298-1307
8. Celermajer D.S., Adams M.R., Clarkson P., Robinson J., McCredie R., Donald A., and Deanfield J.E. Passive smoking and impaired endothelium-dependent arterial dilatation in healthy young adults. N. Engl. J. Med. 334 (1996) 150-154
9. Chalon S., Moreno Jr. H., Benowitz N.L., Hoffman B.B., and Blaschke T.F. Nicotine impairs endothelium-dependent dilatation in human veins in vivo. Clin. Pharmacol. Ther. 67 (2000) 391-397
10. Cucina A., Sapienza P., Corvino V., Borrelli V., Mariani V., Randone B., Santoro D'Angelo L., and Cavallaro A. Nicotine-induced smooth muscle cell proliferation is mediated through bFGF and TGF-beta 1. Surgery 127 (2000) 316-322
11. Demacq C., Metzger I.F., Gerlach R.F., and Tanus-Santos J.E. Inverse relationship between markers of nitric oxide formation and plasma matrix metalloproteinase-9 levels in healthy volunteers. Clin. Chim. Acta 394 (2008) 72-76
12. Ezzati M., and Lopez A.D. Estimates of global mortality attributable to smoking in 2000. Lancet 362 (2003) 847-852
13. Fernandez-Patron C., Radomski M.W., and Davidge S.T. Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ. Res. 85 (1999) 906-911
14. Fernandez-Patron C., Stewart K.G., Zhang Y., Koivunen E., Radomski M.W., and Davidge S.T. Vascular matrix metalloproteinase-2-dependent cleavage of calcitonin gene-related peptide promotes vasoconstriction. Circ. Res. 87 (2000) 670-676
15. Fernandez-Patron C., Zouki C., Whittal R., Chan J.S., Davidge S.T., and Filep J.G. Matrix metalloproteinases regulate neutrophil-endothelial cell adhesion through generation of endothelin-1[1-32]. FASEB J. 15 (2001) 2230-2240
16. Fortuna G.M., Figueiredo-Lopes L., Dias-Junior C.A., Gerlach R.F., and Tanus-Santos J.E. A role for matrix metalloproteinase-9 in the hemodynamic changes following acute pulmonary embolism. Int. J. Cardiol. 114 (2007) 22-27
17. Galis Z.S., and Khatri J.J. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ. Res. 90 (2002) 251-262
18. Garvin P., Nilsson L., Carstensen J., Jonasson L., and Kristenson M. Circulating matrix metalloproteinase-9 is associated with cardiovascular risk factors in a middle-aged normal population. PLoS ONE 3 (2008) e1774
19. Gerlach R.F., Uzuelli J.A., Souza-Tarla C.D., and Tanus-Santos J.E. Effect of anticoagulants on the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Anal. Biochem. 344 (2005) 147-149
20. Gerlach R.F., Demacq C., Jung K., and Tanus-Santos J.E. Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma. Clin. Biochem. 40 (2007) 119-123
21. Golub L.M., Lee H.M., Ryan M.E., Giannobile W.V., Payne J., and Sorsa T. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv. Dent. Res. 12 (1998) 12-26
22. Hamasaki H., Sato J., Masuda H., Tamaoki S., Isotani E., Obayashi S., Udagawa T., and Azuma H. Effect of nicotine on the intimal hyperplasia after endothelial removal of the rabbit carotid artery. Gen. Pharmacol. 28 (1997) 653-659
23. Heeschen C., Jang J.J., Weis M., Pathak A., Kaji S., Hu R.S., Tsao P.S., Johnson F.L., and Cooke J.P. Nicotine stimulates angiogenesis and promotes tumor growth and atherosclerosis. Nat. Med. 7 (2001) 833-839
24. Hui S., Mei Q., and Qiu B. Effects of chronic nicotine ingestion on pressor response to N omega-nitro-L-arginine methyl ester and ex vivo concentration and relaxation response of aorta to L-arginine. Pharmacol. Res. 36 (1997) 451-456
25. Katono T., Kawato T., Tanabe N., Tanaka H., Suzuki N., Kitami S., Morita T., Motohashi M., and Maeno M. Effects of nicotine and lipopolysaccharide on the expression of matrix metalloproteinases, plasminogen activators, and their inhibitors in human osteoblasts. Arch. Oral Biol. 54 (2009) 146-155
26. Li Z., Barrios V., Buchholz J.N., Glenn T.C., and Duckles S.P. Chronic nicotine administration does not affect peripheral vascular reactivity in the rat. J. Pharmacol. Exp. Ther. 271 (1994) 1135-1142
27. Macklin K.D., Maus A.D., Pereira E.F., Albuquerque E.X., and Conti-Fine B.M. Human vascular endothelial cells express functional nicotinic acetylcholine receptors. J. Pharmacol. Exp. Ther. 287 (1998) 435-439
28. Marano G., Ramirez A., Mori I., and Ferrari A.U. Sympathectomy inhibits the vasoactive effects of nicotine in conscious rats. Cardiovasc. Res. 42 (1999) 201-205
29. Martinez A., Oh H.R., Unsworth E.J., Bregonzio C., Saavedra J.M., Stetler-Stevenson W.G., and Cuttitta F. Matrix metalloproteinase-2 cleavage of adrenomedullin produces a vasoconstrictor out of a vasodilator. Biochem. J. 383 (2004) 413-418
30. Martinez M.L., Lopes L.F., Coelho E.B., Nobre F., Rocha J.B., Gerlach R.F., and Tanus-Santos J.E. Lercanidipine reduces matrix metalloproteinase-9 activity in patients with hypertension. J. Cardiovasc. Pharmacol. 47 (2006) 117-122
31. Martinez M.L., Castro M.M., Rizzi E., Fernandes K., Demacq C., Bendhack L.M., Gerlach R.F., and Tanus-Santos J.E. Lercanidipine reduces matrix metalloproteinase-2 activity and reverses vascular dysfunction in renovascular hypertensive rats. Eur. J. Pharmacol. 591 (2008) 224-230
32. Martinez M.L., Rizzi E., Castro M.M., Fernandes K., Bendhack L.M., Gerlach R.F., and Tanus-Santos J.E. Lercanidipine decreases vascular matrix metalloproteinase-2 activity and protects against vascular dysfunction in diabetic rats. Eur. J. Pharmacol. 599 (2008) 110-116
33. Mayhan W.G., and Sharpe G.M. Chronic exposure to nicotine alters endothelium-dependent arteriolar dilatation: effect of superoxide dismutase. J. Appl. Physiol. 86 (1999) 1126-1134
34. Newby A.C. Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. Physiol. Rev. 85 (2005) 1-31
35. Paganelli M.O., Tanus-Santos J.E., Toledo J.C., do Prado J.F., Calegari V., and Moreno Jr. H. Acute administration of nicotine impairs the hypotensive responses to bradykinin in rats. Eur. J. Pharmacol. 413 (2001) 241-246
36. Palei A.C., Zaneti R.A., Fortuna G.M., Gerlach R.F., and Tanus-Santos J.E. Hemodynamic benefits of matrix metalloproteinase-9 inhibition by doxycycline during experimental acute pulmonary embolism. Angiology 56 (2005) 611-617
37. Palei A.C., Sandrim V.C., Cavalli R.C., and Tanus-Santos J.E. Comparative assessment of matrix metalloproteinase (MMP)-2 and MMP-9, and their inhibitors, tissue inhibitors of metalloproteinase (TIMP)-1 and TIMP-2 in preeclampsia and gestational hypertension. Clin. Biochem. 41 (2008) 875-880
38. Perlstein T.S., and Lee R.T. Smoking, metalloproteinases, and vascular disease. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 250-256
39. Piotrkowski B., Koch O.R., De Cavanagh E.M., and Fraga C.G. Cardiac mitochondrial function and tissue remodelling are improved by a non-antihypertensive dose of enalapril in spontaneously hypertensive rats. Free Radic. Res. 43 (2009) 390-399
40. Qiu B.S., Cho C.H., Hui S.C., and Ogle C.W. Chronic nicotine intake increases the responses to muscarinic receptor stimulation. Pharmacology 44 (1992) 41-47
41. Rajagopalan S., Meng X.P., Ramasamy S., Harrison D.G., and Galis Z.S. Reactive oxygen species produced by macrophage-derived foam cells regulate the activity of vascular matrix metalloproteinases in vitro. Implications for atherosclerotic plaque stability. J. Clin. Invest. 98 (1996) 2572-2579
42. Sabha M., Tanus-Santos J.E., Toledo J.C., Cittadino M., Rocha J.C., and Moreno Jr. H. Transdermal nicotine mimics the smoking-induced endothelial dysfunction. Clin. Pharmacol. Ther. 68 (2000) 167-174
43. Shin V.Y., Wu W.K., Chu K.M., Wong H.P., Lam E.K., Tai E.K., Koo M.W., and Cho C.H. Nicotine induces cyclooxygenase-2 and vascular endothelial growth factor receptor-2 in association with tumor-associated invasion and angiogenesis in gastric cancer. Mol. Cancer Res. 3 (2005) 607-615
44. Souza-Tarla C.D., Uzuelli J.A., Machado A.A., Gerlach R.F., and Tanus-Santos J.E. Methodological issues affecting the determination of plasma matrix metalloproteinase (MMP)-2 and MMP-9 activities. Clin. Biochem. 38 (2005) 410-414
45. Souza-Costa D.C., Figueiredo-Lopes L., Alves-Filho J.C., Semprini M.C., Gerlach R.F., Cunha F.Q., and Tanus-Santos J.E. Protective effects of atorvastatin in rat models of acute pulmonary embolism: involvement of matrix metalloproteinase-9. Crit. Care Med. 35 (2007) 239-245
46. Sundstrom J., and Vasan R.S. Circulating biomarkers of extracellular matrix remodeling and risk of atherosclerotic events. Curr. Opin. Lipid. 17 (2006) 45-53
47. Tanus-Santos J.E., Sampaio R.C., Hyslop S., Franchini K.G., and Moreno Jr. H. Endothelin ET(A) receptor antagonism attenuates the pressor effects of nicotine in rats. Eur. J. Pharmacol. 396 (2000) 33-37
48. Van den Steen P.E., Dubois B., Nelissen I., Rudd P.M., Dwek R.A., and Opdenakker G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9). Crit. Rev. Biochem. Mol. Biol. 37 (2002) 375-536
49. Villablanca A.C., McDonald J.M., and Rutledge J.C. Smoking and cardiovascular disease. Clin. Chest Med. 21 (2000) 159-172